Immuno-oncology therapies offer the potential to deliver clinical benefit by utilizing the patient´s immune system to fight cancer. However, therapeutic efficacy can be limited by an immune-cold tumor microenvironment, characterized by absence of immune cell infiltration which is frequently caused by genetic mutations. Within this project, we aim to understand how cancer mutations shape the immune cell microenvironment in lymphoma. Based on this, we aim to discover treatment strategies to restore the immune cell infiltration in subgroups defined by these driver mutations. Specifically, we focus on inhibiting activated SUMOylation, a protein modification which we attributed with immune-modulatory effects. In summary, the scientists aim to establish therapeutic strategies unleashing cancer immunity in lymphoma.